A preoperative clinical prognostic model for non‐metastatic renal cell carcinoma

• Published in: BJU International
• Main Authors: Cindolo, L., De La Taille, A., Messina, G., Romis, L., Abbou, C.C., Altieri, V., Rodriguez, A., Patard, J.J.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2003
• Subjects: Iceland
• Online Access: http://dx.doi.org/10.1111/j.1464-410x.2003.04505.x; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1464-410X.2003.04505.x; http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2003.04505.x/fullpdf

Authors from Naples, Paris and Rennes describe their efforts to develop a model for the preoperative prediction of outcome for non‐metastatic renal cancer. It is valuable to both urologist and patient to develop such a model, particularly so on preoperative criteria. The results of their study are interesting, leading to possibly helpful findings. In another article, authors from Iceland estimated the risk of developing prostate and other cancer among relatives of men from that country diagnosed with prostate cancer. They found that a family history is a risk factor for prostate cancer, with the risk potentially higher for relatives of patients who died from the disease. From the relative dearth of papers on quality of life after radical prostatectomy there are now several, and the authors from Bristol report on the effects of erectile dysfunction on quality of life after this type of treatment. They had a very high response rate (91%) to their questionnaire, and found that erectile dysfunction has a profound effect on quality of life. This finding is not a surprise, but do we need to examine our management of prostate cancer in the light of it? OBJECTIVE To develop a model to predict the outcome before surgery for non‐metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS The records of 660 patients with non‐metastatic RCC, operated at three European medical institutes, were reviewed. Univariate and multivariate analyses were used to assess the clinical and pathological variables affecting disease‐free survival. RESULTS The median (range) follow‐up was 42 (2–180) months; the disease recurred in 110 patients (16%). The 2‐ and 5‐year overall survival was 87% and 54%, respectively. Five variables were significant in the univariate analysis, i.e. clinical presentation, clinical and pathological size, tumour grade and stage ( P < 0.05). The preoperative variables, e.g. clinical presentation and clinical tumour size, were retained from the multivariate model. A recurrence risk formula (RRF) was constructed ...